High-Sensitivity Troponin for Diagnosing NSTEMI

Introduction to High-Sensitivity Troponin

The European Society of Cardiology recommends high-sensitivity cardiac troponin (hs-cTn) measurement in all patients with suspected NSTEMI, with serial measurements at presentation and 1-3 hours allowing rapid rule-in and rule-out of myocardial infarction when integrated with clinical presentation and ECG findings 1

Serial measurements of hs-cTn at 0 and 1-3 hours with both values below the 99th percentile and no dynamic change provide higher diagnostic accuracy than presentation values alone, according to the European Heart Journal 1, 2
The 99th percentile threshold serves as the primary cutoff—values consistently below this with appropriate clinical context safely exclude acute MI, as stated by the European Heart Journal and Circulation 1, 3

Absolute elevation above the 99th percentile plus clinical evidence of myocardial ischemia (symptoms, ECG changes) indicates MI, according to the European Heart Journal 1, 4
Dynamic change of ≥20% between serial measurements (when initial value is already elevated) confirms acute myocardial injury rather than chronic elevation, as stated by Circulation and the European Heart Journal 3, 5

Troponin should be interpreted as a quantitative marker—the higher the level and the greater the absolute change, the higher the likelihood of MI, according to the European Heart Journal 1, 7
Markedly elevated values (>5-fold the upper reference limit, typically >50-100 ng/L) have >90% positive predictive value for type 1 MI, as stated by the European Heart Journal and Circulation 6

At presentation (0 hours), measure hs-cTn immediately with results available within 60 minutes, and if >5-fold upper reference limit (typically >50-100 ng/L) AND ischemic symptoms/ECG changes → rule-in NSTEMI, according to the European Heart Journal and Praxis Medical Insights 1, 6, 8

Chronic troponin elevation (heart failure, renal dysfunction, structural heart disease) requires demonstration of dynamic rise/fall pattern—static elevation alone does not diagnose acute MI, as stated by the European Heart Journal and Praxis Medical Insights 6, 7
Point-of-care troponin tests have lower sensitivity, lower diagnostic accuracy, and lower negative predictive value compared to central laboratory hs-cTn assays—automated central laboratory assays are strongly preferred, according to the European Heart Journal 1, 2
Higher troponin levels correlate directly with increased mortality risk, extent of coronary disease, and benefit from early invasive strategy—use for risk stratification beyond diagnosis, as stated by Circulation and Praxis Medical Insights 3, 5, 8